Compliance and optimisation of oral antidiabetic therapy. A longitudinal study

• Published in: La Presse médicale (1983) Vol. 33; no. 3; pp. 156 - 160
• Main Author: Guillausseau, Pierre-Jean
• Format: Journal Article
• Language: English; French
• Published: France 14.02.2004
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose - analysis; Chi-Square Distribution; Cohort Studies; Data Collection; Data Interpretation, Statistical; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Family Practice; Female; Follow-Up Studies; Gliclazide - administration & dosage; Glycated Hemoglobin A - analysis; Humans; Hypoglycemic Agents - administration & dosage; Longitudinal Studies; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Surveys and Questionnaires; Time Factors
• ISSN: 0755-4982
• DOI: 10.1016/S0755-4982(04)98512-0

To evaluate the impact of optimization of treatment and improvement in observance awareness in patients with type 2 diabetes on compliance with oral antidiabetic drug therapy and long-term glycemic control. Method Evaluation of compliance with oral antidiabetic therapy and of HbA1c levels in a cohort of 4 802 patients with type 2 diabetes followed by their general practitioner, before and after 6 Months on optimized treatment: reduction in percentage of combination treatments from 69.5 to 56.8%, and increase in percentage of once-daily dosing regimen from 12 to 58.4%. Optimization of treatment led to an increase in the percentage of patients achieving optimal compliance with oral antidiabetic drug therapy from 44 to 69.5% after 6 Months (p<0.001). Metabolic control also improved, as evidenced by a decrease in HbA1c levels observed both in the whole cohort (7.5+/-1.6% to 6.9+/-1.2%; p<0.0005), as well as in individual therapeutic subgroups of patients (having switched from multiple-daily dosing to once-daily-dosing schedules and from gliclazide 80 to gliclazide 30 MR once-daily formulation). These findings suggest that optimization of oral antidiabetic therapy favoring the use of oral antidiabetic agents with once-daily dosing administration modalities may improve metabolic control in patients with type 2 diabetes.